Podium to Practice: Chicago 2025 – BREAST: CCTG/BCT MA.40/FINER

Podium to Practice: Chicago 2025 – BREAST: CCTG/BCT MA.40/FINER

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christine Simmons

Icon Chair Speaker

Speakers

Dr. Christine Brezden-Masley

Dr. Heather McArthur

Studies / Trials Discussed

LBA1005 – A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).

This program has been made possible through unrestricted support from Eli Lilly.

Studies/trials discussed:

LBA1005 – A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
Tagged